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ited in this review. A particular focus on phytomedicine, 
also described as herbal therapy and botanical therapy, 
which consists in the use of plant extracts for medicinal 
purposes, is specifically addressed, namely considering 
its history, category of performed studies, tested com-
pounds, active principle and mode of action. The herbs 
already experienced are highly diverse and usually 
selected from products with a long history of employ-
ment against diseases associated with H. pylori  infec-
tion from each country own folk medicine. The studies 
demonstrated that many phytomedicine products have 
an anti-H. pylori  activity and gastroprotective action. Al-
though the mechanism of action is far from being com-
pletely understood, current knowledge correlates the 
beneficial action of herbs with inhibition of essential H. 
pylori  enzymes, modulation of the host immune system 
and with attenuation of inflammation.
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Core tip: Considering the worldwide spread of Helico-
bacter pylori  (H. pylori ) antibiotic resistance, thera-
peutic alternatives beyond antibiotics have been in-
vestigated during the last years, including vaccines, 
probiotics, photodynamic inactivation, phage therapy 
and phytomedicine, which are reviewed in the present 
paper, giving particular attention to phytomedicine. The 
manuscript offers an extensively referenced text about 
the effect of herbal medicines on H. pylori , describing 
the first applications of herbal medicine, passing by the 
category of performed studies, enumerating the tested 
compounds, identifying the active principle and the 
mode of action, and concluding with the limitations and 
promises of this old made new therapy.
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Abstract
Helicobacter pylori  (H. pylori ) successfully colonizes the 
human stomach of the majority of the human popula-
tion. This infection always causes chronic gastritis, but 
may evolve to serious outcomes, such as peptic ulcer, 
gastric carcinoma or mucosa‑ associated lymphoid tis-
sue lymphoma. H. pylori  first line therapy recommend-
ed by the Maastricht-4 Consensus Report comprises the 
use of two antibiotics and a proton-pomp inhibitor, but 
in some regions failure associated with this treatment 
is already undesirable high. Indeed, treatment failure is 
one of the major problems associated with H. pylori  in-
fection and is mainly associated with bacterial antibiotic 
resistance. In order to counteract this situation, some 
effort has been allocated during the last years in the 
investigation of therapeutic alternatives beyond antibi-
otics. These include vaccines, probiotics, photodynamic 
inactivation and phage therapy, which are briefly revis-
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INTRODUCTION 
Helicobacter pylori (H. pylori) infects more than half  of  the 
human population worldwide. Is the etiologic agent of  
peptic ulcer disease in 10%-20% of  the infected indi-
viduals, while 1%-2% are at risk of  developing gastric 
carcinoma or mucosa-associated lymphoid tissue (MALT) 
lymphoma[1]. On a global scale the burden of  disease due 
to H. pylori is huge; elimination of  these bacteria would 
have a major impact on present and future world health. 
Currently, the standard first line clarithromycin-based 
therapy presents undesirable cure rates, and the recent 
guidelines for H. pylori eradication from the Maastricht-4 
Consensus Report do not recommend this therapy in re-
gions with high prevalence of  clarithromycin resistance[2]. 
Current treatments are therefore not an effective strategy 
for worldwide eradication and public health measures 
improving living conditions may help to reduce the trans-
mission of  this infection in selected areas, but will have 
only a limited effect on infected individuals. 
In alternative, infection may be dribbled by the use of  
new treatment approaches, based on ancient alternative 
medicines. This paper addresses the problem of  H. pylori 
infection, the disease-associated spectrum and the antibi-
otic resistance against the current treatment regimens, and 
alternative therapeutic options against resistant strains, 
with special emphasis on phytotherapy approaches.
H. PYLORI BIOLOGY 
The human stomach mucosa is the known ecological 
niche of  H. pylori, a pathogenic spiral-shaped, microaero-
philic, Gram-negative bacterium, which is unique in its 
ability to persist and establish a chronic infection. Dur-
ing colonization, propelled by its flagella and resisting to 
gastric acidity through urease activity, H. pylori crosses 
the gastric mucus layer and adheres to mucins and cells’ 
surface-receptors of  the gastric epithelium. Once here, 
it delivers its virulence factors into the host cells’ cyto-
plasm both through the type-IV secretion system and/or 
by releasing outer membrane vesicles. The cytotoxin-
associated gene A (CagA) and the vacuolating cytotoxin 
(VacA), are among the best studied translocated proteins 
(reviewed in[3]).
In addition to its set of  colonization and virulence 
factors, H. pylori has adapted itself  via complex strategies 
to maintain an inflammation of  the gastric epithelium 
while limiting the extent of  the immune response in or-
der to prevent its elimination, through reduced recogni-
tion by immune sensors, downregulation of  immune cells 
and escape from immune effectors (reviewed in[4]).
Another unique feature of  this bacterium is its tre-
mendous genetic variability, with each strain of  these 
hypermutable bacteria acting as a quasispecies[5,6]. This ge-
nome plasticity is mainly due the bacterium natural com-
petence for transformation and for conjugative transfer of  
genomic islands, resulting in extensive polymorphic genes 
and in differences in gene content among strains[7]. More-
over, H. pylori displays a high frequency of  recombination, 
which in addition to the small size of  the recombined 
fragments results in a mosaic gene structure[8]. Intrage-
nomic recombination has also been reported to occur in 
H. pylori, especially between members of  the large family 
of  paralogous outer membrane proteins (OMP) encoding 
genes or between repetitive sequences, leading to variation 
even in the absence of  mixed colonization[9-11].
Occurrence of  point mutations is another mechanism 
of  genetic diversity in H. pylori, involved for example in 
the development of  antibiotic resistance[12]. It is likely that 
the high rate of  mutation in H. pylori is due to a relative 
deficiency in DNA repair systems, since many of  these 
systems appear to be absent in this organism[13].
H. PYLORI DISEASES AND TREATMENT 
OPTIONS 
In a similar fashion H. pylori is worldwide spread, this bug 
is implicated in a broad spectrum of  diseases, consider-
ing its restrict niche. H. pylori infection of  the human 
stomach, usually occurring in the childhood, will always 
elicit an acute immune response. However, if  left un-
treated, infection and inflammation (gastritis) persist. Al-
though often asymptomatic, gastritis may cause dyspeptic 
symptoms, or it may further progress, causing peptic 
ulcer disease, distal adenocarcinoma and gastric mucosal 
lympho-proliferative diseases such as MALT lymphoma 
in 10%-15% and 2% of  adult patients, respectively[1]. H. 
pylori infection has been linked to diseases localized out-
side of  the stomach as well, with the strongest evidences 
linking infection with cardiovascular diseases, lung dis-
eases[14], hematologic diseases, such as idiopathic throm-
bocytopenic purpura[15], neurological diseases[16] and 
Diabetes Mellitus, although more studies are required to 
clarify such proposed causal links (reviewed in[17]). In ad-
dition, the relationship between bacterial CagA positivity 
and coronary heart disease has been reportedly empha-
sized[18,19]. In contrast, the beneficial effects of  H. pylori 
concerning allergic diseases[20] and obesity appear clear, 
while the association with gastroesophageal reflux disease 
is still controversial[21,22].
H. pylori eradication aims mostly to cure functional-
associated disease, such as peptic ulcer, but is also a strat-
egy to prevent gastric cancer
[23]
.
In an era in which no anti-H. pylori vaccine is yet avail-
able, the treatment relies on the use of  antimicrobials. 
Currently, the first-line treatment of  H. pylori infection 
consists of  two antimicrobials, being the standard com-
bination the use of  amoxicillin with clarithromycin or 
metronidazole, plus a proton-pump inhibitor (PPI). In al-
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ternative, levofloxacin can replace clarithromycin in first-
line therapy, with apparently higher cure rates
[24]
. More-
over, an alternative empiric strategy is mandatory when 
local clarithromycin resistance is higher that 20%
[2]
. When 
the triple schemes fail, a quadruple second-line therapy 
is recommended. The most popular quadruple therapy is 
still the one containing bismuth, consisting of  a combi-
nation of  bismuth salts, tetracycline and metronidazole, 
which is now available in 3-in-1 pill, plus a PPI
[25,26]
. The 
nonbismuth-based quadruple therapy comprises several 
combinations of  antibiotics, administered in a sequential 
or concomitant way. An example is the recent combina-
tion of  levofloxacin, nitazoxanide and doxycycline plus 
the PPI omeprazole, which showed eradication rates of  
around 90%
[27]
.
After failure of  second-line treatment, treatment 
should be guided by antimicrobial susceptibility testing 
whenever possible. 
TREATMENT FAILURE
Treatment failure is one of  the major problems associ-
ated with H. pylori infection and is mainly associated with 
bacterial antibiotic resistance but also because bacteria 
may be in a protective environment like the stomach 
mucus layer or even inside the epithelial cells[28]. Failure 
in therapy may also occur because of  the lack of  patient 
compliance due to non negligible side effects. 
Among the most used antibiotics against H. pylori, 
claritrhomycin is the one that poses higher concerns 
since resistance to this antibiotic decreases the rate of  
success of  the standard therapy to 20%, against 90% 
when the strain is susceptible[29]. Currently, H. pylori re-
sistance to antibiotics is uneven distributed worldwide, 
with higher rates reported in developed countries than in 
developing countries in agreement with prescription fre-
quency. Accordingly, in Europe clarithromycin resistance 
rate has doubled in a 10 years period, from 9.9% in 1998 
to 17.5% in 2008-2009, and it was significantly correlated 
with the outpatient consumption of  long-acting macro-
lides[30,31]. The consumption varied greatly among Eu-
ropean countries and thus the rate of  H. pylori resistant 
strains was also highly heterogeneous. Indeed, the rate of  
resistance strains was found to be significantly higher in 
Western/Central and Southern Europe (> 20%) than in 
Northern European countries (< 10%)[31]. 
Levofloxacin is the other antibiotic for which resis-
tance is also of  concern, since success of  PPI-amoxicil-
lin-levofloxacin regimen decreases radically if  the H. pylori 
strain is resistant to levofloxacin compared with a suscep-
tible strain[32]. Similarly to clartithromycin, the higher the 
consumption of  fluoroquinolones in the community, the 
higher the H. pylori resistance rate to levofloxacin[31].
A high rate of  H. pylori resistant strains to these two 
antibiotics has also been reported in other geographies, 
such as Japan[33], Korea[34], Vietnam[35], China[36] and 
Iran[37], as well as in South America, such as Mexico[38] 
and Brazil[39], mostly for levofloxacin, while there are little 
data concerning US.
Concerning the other antibiotics used to treat H. py-
lori infection, such as amoxicillin, tetracycline and rifam-
picins, the resistance is still rare, probably because the 
implicated point mutations have a high biological cost to 
the bacterium.
As regard to metronidazole, resistance to this antibi-
otic involves complex mechanisms and although it can 
contribute to, it is not directly correlated with treatment 
failure, being overcome in the majority of  the situations 
by changing the associated antibiotics as well as the dos-
age and length of  treatment[40].
ALTERNATIVE THERAPIES 
In light of  the current situation of  a worldwide spread 
of  H. pylori antibiotic resistance, therapeutic alternatives 
beyond antibiotics have been investigated during the last 
years, including vaccines, probiotics, photodynamic in-
activation, phage therapy and phytomedicine. This latest 
further explored below.
Immunization is one of  the most cost-effective and 
successful public health achievements of  the 20th century 
to prevent infectious diseases. Similarly, a prophylactic 
vaccine against H. pylori infection would prevent gastric 
diseases associated with this infection, in particular gas-
tric cancer. Pioneering work in the early 1990s provided 
evidence that vaccination against H. pylori infection was 
possible, based on murine models. The feasibility of  a 
preventive vaccination against H. pylori infection has since 
been proven in other animal models, such as dogs, and 
vaccine candidates against H. pylori infection have been 
tested in humans (reviewed in[41]). The antigens previous-
ly used in attempts to develop a vaccine against H. pylori 
infection were mostly secreted proteins (such as urease or 
VacA) rather than antigens associated with the cell enve-
lope. H. pylori possesses an unusual set of  OMPs reflect-
ing its adaptation to the unique gastric environment[9]. In 
this context, effort should be taken in the evaluation of  
OMPs of  H. pylori as target antigens for a DNA multiva-
lent vaccine construct. 
Probiotics are live organisms or produced substances 
that are orally administered to promote health[42]. In the 
case of  H. pylori infection, their use could be attractive 
mostly to prevent antibiotic side effects, such as diarrhea, 
as well as improve eradication rates. Indeed, probiotics 
can act in several ways in the gut microbiota, for instance 
by direct antagonism to pathogens through the produc-
tion of  inhibitory substances, competition for adhesion 
or nutrients, host immune modulation or inhibition of  
toxins[43,44]. Various probiotics have shown favorable ef-
fects in animal models of  H. pylori infection, by reduc-
ing colonization and alleviating the inflammation of  
the stomach[45,46]. Most of  the studies in humans, using 
combinations of  antibiotics and probiotics showed an 
overall improvement of  H. pylori gastritis and an increase 
in H. pylori eradication, as well as attenuation of  total side 
effects after administration of  probiotics[47,48]. However, 
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complex mixtures of  organic chemicals. Herbal medicine 
origins are based on empirical knowledge, and scientific 
validation of  these products is still very limited[60]. This 
lack of  knowledge and evidence indicating the efficacy 
of  herbal medicine makes it suspicious for western physi-
cians and researchers. The risks and benefits of  herbal 
medicine are incomplete, complex, and confusing. There 
is a need for further controlled clinical trials addressing 
the potential efficacy of  herbal medicine, together with 
understanding the mode of  action and implementation 
of  legislation to maximize their safety and quality[62].
The whole plants and plant extracts used are very 
diverse and typically belong to the natural flora of  a 
specific world’s area. For this reason the use of  search 
motors can easily miss publications owned to the disper-
sion of  key words selected by authors. Our search was 
done on Pubmed and ISI web of  knowledge, from 1983 
to 2013, using the keywords “herbal H. pylori”, “herbs H. 
pylori”, “phytomedicine H. pylori”, “botanical medicine H. 
pylori”, “dietary supplement H. pylori not probiotics” and 
“functional food H. pylori” to find any in vitro and in vivo 
studies evaluating single or compound herbal prepara-
tions in the management of  H. pylori infection. While the 
first four keywords correctly identify the use of  plants or 
plant extracts for the eradication of  H. pylori, the last two 
terms identify mainly the use of  vitamins for eradication 
or slow of  disease progression.
History: A therapy older than H. pylori discover
Phytotherapy is as old as human civilization and for that 
reason telling its early years, that occurred sooner than 
written history, should always lead to an incomplete re-
port. The ancient use of  plants was based on experience, 
since the cause of  illness and the mode of  cure was not 
understood. Until the application of  chemistry to medi-
cine in the 16th century, herbs were the source of  treat-
ment and prophylaxis. Then the use of  herbs gradually 
diminished being replaced by synthetic drugs. In the last 
three decades there was another inversion, owing to the 
increasing of  resistance of  microorganisms to drugs[63]. 
Even long before the identification of  H. pylori in the 
beginning of  the early 1980s[64,65] herbs have been used to 
deal with diseases that today are known to be associated 
with H. pylori infection[66,67]. This is the case of  the use of  
Symphitum officinalis and Calendula officinalis to treat a group 
of  patients with duodenal ulcer or gastroduodenitis. In 
this trial, a group of  patients received the herbs and an 
antiacid, while the control group just received the herbs. 
The pains disappear in both groups, but earlier in the 
group that received the antiacid[67]. In fact, the reduction 
of  acid production was central in the therapy of  peptic 
ulcer. Several drugs that act as anticholinergic or antimus-
carinic, that reduce gastric acid secretion, were used in 
an attempt to replace parietal cell vagotomy, in which the 
resection of  the vagus nerve led to the reduction of  the 
production of  acid by the parietal cells of  the stomach[68], 
including the use of  herbs, such as belladonna (Atropa bel-
ladonna L. or its variety acuminata Royle ex Lindl)[69].
no study could demonstrate complete eradication of  H. 
pylori infection by probiotic treatment. Finally, long-term 
intakes of  products containing probiotic strains may have 
a favorable effect on H. pylori infection, particularly by 
reducing the risk of  developing gastric inflammation-
associated disorders. 
More unconventional alternative anti-H. pylori treat-
ments have revisited some “old” technologies, such as 
photodynamic inactivation and phage therapy, both 
dating long before the golden era of  antibiotics. Photo-
dynamic therapy (PDT) uses a photosensitizer and light 
sources of  specific wavelengths to treat malignant tumors 
or localized infectious diseases. The reactive oxygen spe-
cies generated by the photodynamic reaction will induce 
damage to multiple cellular structures, with bactericidal 
effects[49]. The bactericidal effect of  PDT is well known 
against Gram-positive bacteria but usually inactive against 
Gram-negative bacteria. However, H. pylori displays two 
characteristics that turn it susceptible to PDA: its natural 
ability to accumulate photoactive porphyrins and lack of  
genes to repair phototoxicity-induced DNA damage[50]. 
Therefore, efficient H. pylori killing is possible just by low 
fluency of  broad-spectrum conventional white endo-
scopic light[51]. Moreover, the localization of  the infection 
in the gastric mucosa facilitates the endoscopic access for 
light delivery. A recent study showed that the bactericidal 
activity of  PDT against H. pylori involved cell membrane 
injury[52]. 
Phage therapy consists of  the use of  lytic bacterio-
phages to treat infectious diseases[53]. The description of  
phages in H. pylori is still limited, although is a growing 
field, prompted by the recent description of  a temper-
ate phage of  H. pylori, induced by UV[54], and with the 
sequences of  complete[55-57] and remnant prophages pro-
vided by whole genome sequencing of  H. pylori strains[58]. 
Nevertheless, there is no information on the nature of  
the life cycle of  the described H. pylori phages, and there-
fore of  their potential usage in phage therapy. An alterna-
tive would be the use of  phage lytic proteins, such as a 
lysin, which is responsible for the lysis of  host bacterial 
cell wall. However, lysins would have to be modified in 
order to overcome the limitation of  crossing the Gram-
negative outer membrane, as it was described for another 
bacterial species[59].
PHYTOTHERAPY 
Phytotherapy, also described as herbal therapy or botani-
cal therapy, consists in the use of  plants or plant extracts 
for medicinal purposes[60]. Herbal products include raw or 
processed parts of  plants, such as leaves, stems, flowers, 
roots, and seeds. According to legislation herbs are con-
sidered dietary supplements that can be marketed without 
previous demonstration of  safety and efficacy[61]. Western 
medicine typically employs an active principal, often of  
synthetic origin, for therapy proposes. On the opposite, 
in phytotherapy applications rarely the active principle is 
either identified or administrated solely. Instead herbs are 
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Presently, three decades after the discovery of  H. 
pylori, herbs are still being used for stomach diseases but 
not all of  them have been tested either in vitro or in vivo 
for their anti-H. pylori activity yet. For instance this is the 
case of  African São Tomé plants, such as Leonotis nepetifo-
lia (L.) W. T. Ainton var. nepetifolia (gastric indisposition), 
Solenostenom monastachyus (P. Beauv.) Briq. subsp. monos-
tachyus (stomach pain), Piper umbellatum L. (stomach prob-
lems), Bertiera racemosa (G. Don) K. Shum var. elephantina 
N. Hallé (stomach pain), Allophyllus grandifolius (Baker) 
Radlk (gastric affection), and Solanum gilo Raddi (stomach 
pain)[70]. 
Category of performed studies
The study of  phytotherapy products is typically subdi-
vided in two groups, one based on in vitro testing using 
H. pylori pure cultures obtained from clinical isolates or 
reference strains; another based on in vivo tests, in which 
the herbal products are administered to animal models 
or used in clinical trials involving humans. The first stud-
ies are more abundant in the literature namely because 
of  their simplicity, cost, legislation demands and to early 
years of  studding herbal products in a similar way to 
western medicine products.
Concerning preparation of  plants extracts, these are 
prepared usually by drying and reduce to fine powder 
which is then dissolved in a solvent, such aqueous etha-
nol or methanol, sonicated, filtered or centrifuged and 
the solvent evaporated. The herbal residue is dissolved in 
dimethyl sulfoxide (DMSO)[71,72]. Different concentration 
of  plant extracts are mixed with a bacterial suspension of  
H. pylori for 1h and plated in standard H. pylori medium. 
The minimum bactericidal concentration corresponds to 
the test sample at which there was no visible growth[71]. 
Alternatively, wells can be punched on the plates and the 
herbal extract introduced; extract embedded paper discs 
are another option. The inhibitory action is evaluated 
by determination of  the clear zone around each well or 
disc[72]. For the in vitro test, the 96-well micro-titer plates 
cultured micro-aerobically can also be used[73]. Regard-
ing the negative and the positive control, DMSO may be 
used as negative control[71,72], while standard antibiotic 
agents can be applied as positive control[74].
Other in vitro assays include the use of  gastric epithe-
lial cells, such as AGS cells[75,76] or macrophage cells, like 
RAW264.7[75,77], or HeLA cells[78]. In this assays eukaryotic 
cells are treated with herbal extracts followed by infec-
tion with H. pylori (multiplicity of  infection 1:100), for 
instance during 6h. Then several parameters of  infection 
can be determined to understand if  the herbal plants 
interfere with their concentration. These parameters in-
clude nuclear factor ĸB (NF-ĸb) and cytokines, such as 
interleukin-8, tumor necrosis factor-α, nitric oxide (NO) 
production and expression levels of  inflammation related 
proteins inducible NO synthase and cyclooxygenase[74]. 
The effect of  the herbal compound on bacterial adhe-
sion and invasion of  epithelial cells may also be deter-
mined[74,79]. The effect of  herbal extracts on cell-adhesion 
is determined by removing unbound bacteria using a 
series of  washes in phosphate-buffered saline, followed 
by cell lysis with distilled water. The lysates are then plat-
ted on H. pylori appropriate medium and colony forming 
units determined. To verify the effect on the number of  
viable intracellular bacteria, infected epithelial cells are 
treated with the membrane impermeable antibiotic gen-
tamicin in order to eliminate external bacteria. Then the 
same procedure is applied and the colony forming units 
determined. Appropriate controls without herbal extracts 
and without gentamicin should be performed, so that 
these may be considered as total adhesion or invasion[79]. 
The [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] (MTT) viability assay may be used to measure 
the cytotoxicity of  tested agents[75]. 
Animal models may also be used to understand the 
action of  herbal medicine on gastric colonization by H. 
pylori and gastric pathology. In those, such as the Mon-
golian gerbil[80-83], the specific-pathogen-free mice[78,84,85], 
or the Wistar albino rat[86,87], animals are infected with 
H. pylori strains and treated with different doses of  plant 
extracts. After sacrifice the eradication or decrease in the 
number of  H. pylori colonies may be determined. Further 
histopathological analysis can also be performed in sec-
tions of  the stomach fixed in formalin and embedded in 
paraffin.
A summary of  clinical trials using different plant ex-
tracts is presented in Table 1. In these trials a plant extract 
is tested in opposition to a placebo or, more recently, in 
addition to conventional triple therapy. In these studies 
there is no evidence of  statistical significant improvement 
in eradication when herbs are used. Nonetheless these 
studies are still few, involving a small number of  patients 
and moreover applied as a supplement to antibiotic triple 
therapy that is known to eradicate H. pylori in the great 
majority of  the cases.
From Table 1 only the study of  Puram et al[88] uses 
herbal medicine (GutGard) alone against a control group 
receiving placebo. Although the eradication rate is evi-
dent in the group receiving GutGard (56%) against 4% 
in the placebo group[88], it is still lower to the eradication 
obtained using triple therapy. Nevertheless, it should be 
emphasized that the treatment with GutGard was found 
to be 3.73 times more effective than placebo.
Detail attention should be given to data on clini-
cal trials. For instance in the study of  Salem et al[89], two 
recruited patients were positive for H. pylori after two 
consecutive triple therapy courses, but they changed to 
negative after receiving N. sativa treatment in a dose of  
3 g/d along with 40 mg omeprazole for four weeks, H. 
pylori status evaluated by stool antigen test. 
A systematic review of  the use of  traditional Chinese 
medicine against H. pylori[90] analyzed 16 randomized clin-
ical trials using several different herbs with proton pump 
inhibitor or colloidal bismuth subcitrate based triple ther-
apy as controls. The heterogeneity of  the studies did not 
allow a meta-analysis. Overall, conventional triple therapy 
originated higher eradication rate than Chinese medicine, 
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and the opposite is observed for secondary effects, favor-
ing Chinese medicine.
From the clinical trials analysis it is not possible to 
completely understand the efficacy of  the herbs used, 
namely because of  the poor quality of  the trials[90]. Only 
the extension of  the requirements of  evidence-based 
medicine to phytomedicine clinical trials would allow as-
sessing with accuracy the efficacy of  the herbal extracts.
  Herb Study design Sample Experimental 
intervention
Control Outcome Difference between experimental 
and control group
Ref.
  Garlic oil Blind non-
randomized 
trial
20 dyspeptic 
patients
27 mg garlic oil 3 
times a day for 14 
d
Same plus 20 mg 
omeprazole
Negative for histology 
and urease test
No Symptom score (8.7 ± 
1.70 vs 8. ± 1.1) and H. 
pylori density (2.0 ± 0.82 
vs 2.1 ± 0.74) did not 
significantly changed
[111]
  Fresh garlic 
  or jalapeno 
  peppers 
Open non-
randomized 
trial
12 healthy 
patients with 
H. pylori
10 cloves fresh 
garlic or  
jalapeno peppers 
with 3 meals per 
test day
Bismuth 
subsalicylate with 
3 meals per
Reduction in urea breath 
test counts
Garlic and jalapeno 
add no effect (P > 
0.8), but significant 
reduction after bismuth 
(P < 0.001)
[112]
  Cinnamon Blinding 
placebo-
controlled
23 patients 
undergoing 
gastroscopy
40 mg cinnamon 
extract twice a day 
for 4 wk
test day or no 
intervention
Placebo
Reduction in urea breath 
test counts
No Mean urea breath test 
reading (23.9 vs 2.9) 
did not significantly 
changed
[109]
  Lycopene Quasi-control 
trial
4 patients 
with H. pylori
Metronidazole 
00 mg/bd, 
amoxicillin 1g/bd, 
omeprazole 20 
mg/bd, bismuth 
240 mg/bd, and 
lycopene 30 mg/
daily
Metronidazole 
00 mg/bd, 
Amoxicillin 1 g/
bd, Omeprazole 
20 mg/bd, 
Bismuth 240 
mg/bd
Slight increased 
eradication rate with 
lycopene (no statistical 
difference) evaluated by 
urease rapid test
No 
statistical 
difference
[113]
  Nigella sativa 
  (N. sativa)
Randomized 
trial
88 dyspeptic 
patients
Triple 
therapy (TT:  
clarithromycin 
00 mg twice 
daily, amoxicillin 
1g twice daily, 
omeprazole 40 mg 
once daily) and 1, 
2 or 3 g N. sativa
Clarithromycin 
00 mg twice 
daily, amoxicillin 
1g twice daily, 
omeprazole 40 
mg once daily
2 g/d and TT no 
statistical difference
1 g/d and 3 g/d 
significantly less 
effective than TT by 
stool antigen test
No Eradication rates with 2 
g N. sativa and TT with 
no statistical difference; 
eradication rate with 
1g or 3 g N. sativa was 
significantly less than 
that with TT (P < 0.0)
[89]
  Green 
  propolis
Non-
randomized 
clinical trial
18 patients 
infected with 
H. pylori
20 drops of 
alcoholic 
preparation of 
Brazilian green 
propolis 3 times a 
day for 7 d
No One patient negative 
for H. pylori 40 d after 
treatment
Not 
applicable
[108]
  Glycyrrhiza 
  glabra
Randomized 
double blind 
placebo 
controlled 
trial
107 patients 
infected with 
H. pylori
 patients – 10 
mg of GutGard 
(root extract of G. 
glabra) once daily 
for 0 d
2 patients - 
placebo once 
daily for 0 d
% of patients 
receiving GutGard 
eradicate H. pylori vs 4% 
on placebo
Yes Asignificant interaction 
effect between group 
and time (P = 0.00)
[88]
  Chinese 
  patent 
  medicine 
  wenweishu 
  /yangweishu
Randomized, 
controlled and 
multicenter 
trial
42 patients 
infected with 
H. pylori
PCM plus 
wenweishu 
group (n = 19); 
and PCM plus 
yangweishu 
group (n = 224)
PCM group 
(n = 222, 
pantoprazole 40 
mg twice a day, 
clarithromycin 
00 mg 
twice a day, 
metronidazole 
400 mg twice a 
day, for 7 d)
Higher healing rate in 
PCM plus wenweishu;
Higher  rates of 
symptom relief in PCM 
plus wenweishu and 
PCM plus yangweishu; 
Eradication rate 
between PMC group 
and PMC plus 
wenweishu or PMC 
plus yangweishu group 
was not significantly 
different (P = 0.108, 
0.32, respectively)
Yes Healing rate in PCM 
plus wenweishu 
groups was 
significantly higher 
than the rate in PCM 
group (P = 0.004)
Symptom relief rates in 
PCM plus wenweishu 
groups and PCM plus 
yangweishu were 
significantly higher 
than the rate in PCM 
group (both P < 0.01)
[110]
Table 1  Examples of clinical trials using herbal medicines
PCM: Pantoprazole, clarithromycin, metronidazole; H. pylori: Helicobacter pylori.
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Table 2  Herbal medicines tested against Helicobacter pylori
Herb Study type Result Observation Active principle Mechanism of action Ref.
Garlic In vivo clinical trial No improved 
eradication (consult 
Table 1)
NA NA NA [111,112]
Pelargonium sidoides 
roots (eps) 730
In vitro using AGS 
cells and in situ using 
biopsies
Inhibit H. pylori growth 
and cell adhesion
South African herbal 
remedy
NA Anti-adhesive activity [114,11]
Cranberry juice In vitro using 
immobilized 
human mucus and 
erythrocytes
Inhibit H. pylori cell 
adhesion
NA NA Anti-adhesive activity 
(sialic acid-specific 
adhesion)
[11,117]
Oregano and 
cranberry
In vitro agar difusion 
assay
Inhibition zones on 
agar plate
NA Phenolic compounds Urease inhibition; 
disruption of energy 
production inhibiting 
proline dehydrogenase 
at the plasma 
membrane
[93]
Magnolia officinalis 
Rehd. Et Wils. 
(Magnoliaceae) and 
Cassia obtusifolia L. 
(Leguminosae)
Compounds tested 
against Jack bean 
urease
Inhibit urease Chinese medicinal 
herbs
Hydroxamic acids, 
phosphoramidates, 
urea derivatives, 
quinones, and 
heterocyclic 
compounds
Inhibit urease [118]
Camellia sinensis In vitro test against H. 
pylori, urease activity 
assay
Inhibit urease; 
reduction of H. pylori 
population
Tea leaves Polyphenolic 
compounds and 
catechin contents 
(epicatechin,
Inhibit urease [94]
Apple peel 
polyphenols 
Compounds tested 
against Jack bean 
urease; in vitro test 
against H. pylori; in 
vitro test using hela 
cells; in vivo test using 
C7BL/J mice
Inhibit urease; 
prevented vacuolation 
in hela cells; 
antiadhesive effect; 
anti-inflammatory 
effect
NA epigallocatechin, 
epicatechin gallate, 
pigallocatechin
gallate)
Polyphenols
Inhibit urease; anti-
adhesive activity
[78,9]
Calophyllum 
brasiliense Camb. 
(Clusiaceae)
In vitro disk diffusion; 
in vivo using  Wistar 
rats infected with H. 
pylori
Dose-dependent 
reduction of ulcerated 
area; decreased 
number of urease-
positive animals; 
partial anti-H. pylori 
inhibition
Large tree widely 
distributed in Latin 
America known in 
Brazil as "guanandi"
Mixture of chromanone 
acids
Inhibit urease; 
modulation of 
endogenous antioxidant 
systems
[8,87]
Mouriri elliptica 
Martius 
(Melastomataceae)
In vivo Swiss albino 
mice and male Wistar 
albino rats animal
Gastric protective 
action without 
antisecretory effect; 
anti-H. pylori action
Brazilian fruit-
bearing plant of 
known as “coroa-de-
frade”
Acid derivatives, 
acylglycoflavonoids 
and condensed tannins
Inhibit NO production 
by macrophages; 
stimulating 
proliferation factors 
(PCNA), COX-2
[119]
Hancornia speciosa 
Gomez (Mangaba)
In vivo Swiss albino 
mice and male Wistar 
albino rats animal
Antiulcer activity Medium-sized 
tree (3–10 m) from 
central Brazil, known 
as “mangaba”, 
“mangabeira” or 
“mangava”
Polymeric 
proanthocyanidins
Increase pH and 
decrease acid output of 
gastric juice, stimulate 
mucus synthesis and 
produce antisecretory 
effect
[120]
Byrsonima 
fagifolia Nied. 
(Malpighiaceae)  
In vivo Swiss albino 
mice and male Wistar 
albino rats animal
In vitro disc diffusion 
technique
Gastric protective 
action; anti-
inflammatory effect; 
anti-H. pylori action
Brazilian herb 
known as "murici" or 
"murici-do-mato"
Phenolic compounds, 
flavonoids, gallic acid 
derivatives
Antioxidant properties [97]
Alchornea triplinervia In vivo mouse model Antisecretory property; 
anti-H. pylori effect; 
gastroprotective action
Medicinal plant from 
Brazil
Flavonoids Antisecretory action,  
increase of gastric 
mucosa prostaglandin 
E(2) levels
[9]
Amphipterygium 
adstringens 
(Schltdl.) Standl. 
(Anacardiaceae)
In vitro killing assay Exhibits potent dose-
dependent anti-H. 
pylori activity
Mexican folk 
medicine
Anacardic acids 
mixture
NA [121]
Extract of Japanese 
rice also
In vivo Mongolian 
gerbil model
Anti-H. pylori activity; 
anti-inflammatory 
effect
NA NA NA [122]
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1 Mexican plants1 In vitro broth 
microdilution 
method
Anti-H. pylori activity Mexican folk 
medicine
NA NA [123]
Bacopa monniera In vitro broth 
microdilution 
method
Anti-H. pylori activity In Ayurveda, 
(ancient medicine 
of India) known as 
medhya rasayana or 
"brahmi"
NA Augmentation of 
defensive mucosal: 
mucin secretion, life 
span of mucosal cells, 
and gastric antioxidant
[124]
Propolis In vitro test against H. 
pylori
Test against 
Recombinant 
protein (peptide 
deformylase)
Anti-H. pylori activity Resinous hive 
product collected by 
honeybees
Phenolic compounds, 
mainly Caffeic acid 
phenethyl ester (CAPE)
CAPE is a competitive 
inhibitor of H. pylori 
peptide deformylase
[107,12]
Gosyuyu (Wu-Chu-
Yu) and Psoralen 
(extract from 
Psoralea corylifolia)
In vitro test against H. 
pylori
Anti-H. pylori activity Chinese herbal 
medicine, namely 
“buguzhi”
Alkyl methyl 
quinolone alkaloids
NA [12]
Amu-ru 7, a In vitro test against H. 
pylori
In vivo Mongolian 
gerbil
Anti-H. pylori activity
Did not cure 
Mongolian gerbil, 
but colonization rate 
diminish
Mongolian folk 
medicine
Alkyl methyl 
quinolone alkaloids
Rhei rhizome is the most 
effective component
Inhibited biofilm 
formation by H. pylori 
partial inhibition of 
urease
[127]
Agrimonia eupatoria, 
Hydrastis canadensis, 
Filipendula ulmaria, 
and Salvia officinalis
In vitro test against H. 
pylori
Anti-H. pylori activity Western herbal 
medicine
NA NA [128]
Curcumin 
diferuloylmethane
In vitro test against H. 
pylori
In vitro using AGS 
cells
In vivo C7BL/ mice 
and Male Sprague-
Dawley rats
In vitro anti-H. pylori 
activity; effective in 
eradication of H. pylori 
from infected mice and 
in restoration of H. 
pylori-induced gastric 
damage
The major yellow 
pigment present 
in the rhizome 
of turmeric (the 
perennial herb 
Curcuma longa)
Diferuloylmethane Suppressing secretion 
of metalloproteinases 
3 and 9 by gastric 
cells noncompetitive 
inhibitor of H. 
pylori shikimate 
dehydrogenase, among 
others decrease nuclear 
factor-kB (NF-κB) p
[7,10,129]
Nigella sativa 
(Ranunculaceae) 
In vivo adult patients Administrated with 
omeprazole had a 
eradication rate similar 
to triple therapy 
(consult Table 1)
Grows in the Middle 
East, Eastern Europe, 
and Eastern and 
Middle Asia
Thymoquinone, 
dihydrothymoquinone 
and terpenes
Disrupting the lipid 
structure of the cell 
membrane
[89]
Methanol extract of 
the leaf of Allium 
ascalonicum 
In vitro test against H. 
pylori
Anti-H. pylori activity Known as garlic Alkaloids, cardiac 
glycosides and 
saponins
Decrease urease activity [130]
Leaves of Piper 
carpunya Ruiz and 
Pav. (syn Piper 
lenticellosum C.D.C.) 
(Piperaceae)
In vitro test against H. 
pylori
In vitro against rat 
peritoneal leukocytes
Anti-inflammatory; 
anti-ulcer action
Widely used in folk 
medicine in tropical 
and subtropical 
South American
Flavonoids Inhibition of H+, K+-
ATPase activity
[98,99]
Apium graveolens 
seeds 
In vitro test against H. 
pylori
Anti-H. pylori activity Used in Ayurvedic 
medicine
Compound with anti-
Helicobacter activity, 
an asymmetric 
phthalide dimer
Induces morphologic 
changes in H. pylori and 
inhibits protein and 
DNA synthesis
[131]
Davilla elliptica and 
Davilla nitida 
In vivo Swiss albino 
mice and male Wistar 
albino rats animal
In vitro disc diffusion 
technique
Anti-H. pylori activity; 
gastric protection 
action
Brazil folk medicine Phenolic acid 
derivatives, 
acylglycoflavonoids, 
and condensed tannins
Stimulats moderate 
levels of H2O2, trigger 
moderation of the 
oxidative burst and 
consequently the 
immune response
[132]
Resveratrol In vitro test against H. 
pylori
In vitro  using 
MKN-4 cells
Inhibit urease, anti-
inflammatory and 
anti-cancer activity 
cardioprotective 
and neuroprotective 
properties
highly abundant in 
red grapes
Polyphenol Modulation of 
interleukin (IL)-, 
NF-κB, and mitogen-
activated protein 
kinases;  modulatory 
effects on H. pylori-
induced IL-8 secretion, 
reactive oxygen species 
production, and 
morphological changes
[102,103,133,
134-13]
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Anisomeles indica In vitro test against H. 
pylori
In vitro using AGS 
cells
Anti-H. pylori activity; 
anti-inflammatory 
properties
From Southeast Asia 
and Australia
Ovatodiolide Attenuated the 
inflammatory response 
by decreasing NF-
κB activation and 
IL-8 secretion, inhibit 
lipopolysaccharide-
induced inflammation 
in macrophages 
(including the 
secretion of the pro-
inflammatory cytokine 
tumor necrosis factor-α, 
and nitric oxide (NO) 
production, and 
protein expressions of 
inducible NO synthase 
and cyclooxygenase-2 
(COX-2)
[7]
Glycyrrhiza glabra In vitro test against H. 
pylori
In vitro using AGS 
cells
In vivo adult patients
Anti-H. pylori activity; 
anti-inflammatory 
properties (consult 
Table 1)
Legume known 
as licorice from 
southern Europe and 
parts of Asia
Flavenoid, main 
component 
glycyrrhetinic acid
Inhibition H. pylori 
of DNA gyrase, 
protein synthesis 
and dihydrofolate 
reductase enzyme; 
anti-inflammatory 
activity likely through 
inhibition of COX and 
lipoxygenase pathways
[88,100]
Cistus laurifolius In vitro test against H. 
pylori
Anti-H. pylori activity Folk medicine in 
Anatolia
Flavenoid, most active 
is quercetin 3-methyl 
ether (isorhamnetin)
NA [137]
Sclerocarya birrea In vitro test against H. 
pylori
Anti-H. pylori activity Medicinal plant 
used by Zulus, 
Vhavendas, Xhosas 
and Sothos of South 
Africa
Essential oils:  
terpinen-4-ol (3.83%), 
pyrrolidine (32.1%), 
aromadendrene 
(13.3%) and 
α-gurjunene (8.77%)
NA [138]
Phyllanthus urinaria In vitro test against H. 
pylori
In vitro using AGS 
cells
Anti-H. pylori activity; 
anti-inflammatory 
properties
Tropical and 
subtropical countries 
(Taiwan)
Phyllanthin, 
phyltetralin, trimethyl-
3,4-dehydrochebulate, 
methylgallate, 
rhamnocitrin, methyl 
brevifolincarboxylate, 
β-sitosterol-3-O-β-
d-glucopyranoside, 
quercitrin and rutin
Inhibits AGS cells 
adhesion and invasion; 
decreases NF-κB 
activation and IL-8 
secretion
[139,140]
Artemisia douglasiana 
Besser (Asteraceae)
In vitro test against H. 
pylori
Anti-H. pylori activity Folk medicine in 
Argentina known as 
"matico"
Dehydroleucodine, a 
sesquiterpene lactone 
of the guiainolide type
Potent inhibitors of the 
transcription factor NF-
κB
[141,142]
Geranium wilfordii In vitro test against H. 
pylori
Anti-H. pylori activity Herb from China Corilagin (1), and 
1,2,3,-tetra-O-galloyl-
β-D-glucose
NA [143]
HZJW, composed of 
12 medicinal herbs
In vitro test against H. 
pylori
In vivo Balb/c mice
Anti-H. pylori activity; 
reduction of ulcerative 
lesion; eradicate H. 
pylori in mice
Chinese herbal 
formula composed of 
12 herbs listed in (91)
Protoberberine 
alkaloids palmatine, 
coptisine and 
aporphinoid alkaloid 
of magnoflorine
NA [91]
Cratoxylum 
arborescens (Vahl) 
Blume
In vitro test against H. 
pylori
In vivo Balb/c mice
Anti-H. pylori activity, 
anti-inflammatory 
activity; reduced ulcer 
area, higher mucus 
content
Asian herbal 
medicine
α-mangostin (AM), is a 
prenylated xanthone
Anti-COX-2 and anti-
NO activities
[144]
Chenopodium 
ambrosioides L. And 
Adina pilulifera.
Chenopodium 
ambrosioides L.
In vitro test against H. 
pylori
Anti-H. pylori activity Jinghua Weikang
Capsule (Chinese 
patent drug for 
peptic ulcer
NA NA [14]
Momordica 
cochinchinensis 
Springer 
(Cucurbitaceae)
In vivo mice Gastroprotective effect Momordica saponin I NA [14]
10 May 21, 2014|Volume 20|Issue 19|WJG|www.wjgnet.com
Tested compounds
There is a high diversity of  tested compounds (Table 2) 
against H. pylori using diverse experimental approaches. 
The era of  blind screening of  compounds come to an 
end, the natural resources screening being no exception, 
so it is rational to use folk medicine plants. The major-
ity of  the studies report the use of  herbs from China, 
given that the traditional Chinese medicine is a common 
practice in this country. Latin American countries come 
in second place, another continent with a rich history in 
medicinal plants usage. Usually each country studies its 
own herbs from folk medicine. So it is understandable 
the diversity of  medicinal plants already tested or cur-
rently being tested. 
The access to the information is not always an easy 
task. Effectively, many papers have only the abstract in 
English language, which difficult the access to informa-
tion by the global scientific community.
Considering the high diversity of  herbal medicines 
used, finding all papers reporting their use is not straight-
forward. In fact, the keywords associated with each study 
not always include general terms, but the name of  the 
species used or its active compound. We suggest that 
studies analyzing the efficacy of  plant extracts include the 
keywords phytomedicine, phytotherapy, herbal medicine 
or herb medicine, in order to turn papers’ identification 
easier.
Most studies report the in vitro efficacy of  the herbal 
therapy against H. pylori, but this isn’t always followed 
by an effective eradication of  the bacterium in animal 
models and/or clinical trials (Table 2). The clearance of  
H. pylori from the stomach of  infected patients occurs by 
direct topical activity of  the ingested drugs at the gastric 
mucosal epithelium, and specially by the systemic thera-
peutic activity, which result from the back secretion and 
re-entry of  the absorbed active principle from the basal 
to the apical side of  the gastric epithelium[91]. The ineffi-
ciency of  the herbal product in an in vivo test after proved 
efficient in an in vitro test against H. pylori may be due 
to the inability of  the compound to resist to the acidic 
medium of  the stomach, inability to reach the bacteria 
trough the mucus layer secreted by the gastric mucosa 
epithelial cells (the thickness of  the mucus layer or its 
impermeability to herbs at the site of  infection), use of  
insufficient dose or to its inability to reach the bacteria via 
systemic circulation.
Active principle and mode of action
The active ingredient is not always identified; sometimes 
the group of  compounds, but not the exact formula, is 
identified. The most common active principle identified 
belong to the group of  flavonoids (Table 2). Flavonoids 
are widely distributed in plants and are recognized as 
the pigments responsible for the colours of  leaves, espe-
cially in autumn (yellow). Flavonoids have low molecular 
weight and are composed of  a three-ring structure with 
various substitutions. The flavonoids are recognized to 
possess anti-inflammatory, antioxidant, antiallergic, hepat-
oprotective, antithrombotic, antiviral, and anticarcinogen-
ic activities. The flavonoids are phenolic compounds and, 
therefore, act as potent metal chelators and free radical 
scavengers[92]. These properties are again evidenced in the 
studies present in Table 2.
The mode of  action of  the herbs can be through 
the inhibition of  essential bacterial enzymes. Some ex-
amples are given. Considering H. pylori, some flavonoids 
have also demonstrated inhibitory effects on bacterium 
growth[78,80,88,93-100], on H. pylori DNA gyrase[88,100] and ure-
ase[78,93,95,99], and vacuolation activity[99]. H. pylori induces 
gastric epithelial cell apoptosis via secreted mediators 
such as the VacA cytotoxin and lipopolysacccharides, 
damaging epithelial acid-secreting parietal cells[101]. Several 
flavonoids may inhibit the apoptotic signaling induced 
by H. pylori VacA toxin[99]. Since urease of  H. pylori is es-
Sangre de grado 
(Croton lecheleri and 
Croton palanostigma)
In vitro test against H. 
pylori
In vivo C7BL/ mice
Anti-H. pylori activity
No bactericidal effect 
in mice
Sangre de grado is 
a red, viscous latex 
from the cortex 
of trees used in 
Peruvian medicine
NA Mice with higher 
hepatic metallothionein 
levels
[147]
Polygonum 
tinctorium Lour
In vitro test against H. 
pylori
In vivo Mongolian 
gerbil
Anti-H. pylori activity; 
anti-inflammatory 
effect; decreased 
bacterial load in 
Mongolian gerbil
Known as indigo Tryptanthrin and 
kaempferol (flavenoid)
Inhibition of nitric 
oxide production, and 
the transcription of 
cyclooxygenase
[80]
Artocarpus obtusus 
Jarret
In vitro test against H. 
pylori
In vivo Mongolian 
gerbil
Anti-H. pylori activity; 
gastroprotective effect; 
increased mucus 
content
Endemic species of 
Borneo known as 
“pala tupai”
Pyranocycloartobiloxa
nthone A, a xanthone
Free radical scavenging 
effect, induction 
of HSP70, via anti-
apoptotic property 
(down regulate bax 
gene), inhibits Cox-2 
enzyme
[148]
Punica granatum and 
Juglans regia
In vitro test against H. 
pylori
Anti-H. pylori activity Iranian plants NA NA [149]
1Castella tortuosa, Amphipterygium adstringens, Ibervillea sonorae, Pscalium decompositum, Krameria erecta, Selaginella lepidophylla, Pimpinella anisum, Marrubium 
vulgare, Ambrosia confertiflora, Couterea latiflora, Byophyllum pinnatum, Tecoma stans linnaeus, Kohleria deppena, Jatropha cuneata, Chenopodium ambrosoides, and 
Taxodium macronatum. NA: Not applicable; H. pylori: Helicobacter pylori.
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sential for its colonization, the inhibition of  this enzyme 
explains partly the anti-H. pylori activity[83]. Resveratrol, 
which inhibits H. pylori in vitro and is present in grapes 
and red wine[102], inhibits urease enzyme as well[103]. Res-
veratrol also targets bacterial ATPases, which protect H. 
pylori from low pH levels by maintaining a proton gradi-
ent across membranes[104]. These results suggest that the 
consumption of  grape extracts and wine constituents, 
in addition to triple therapy, might be useful in the treat-
ment of  H. pylori infection[105].
The H. pylori shikimate dehydrogenase, present in the 
shikimate pathway is essential for the synthesis of  impor-
tant metabolites, such as aromatic amino acids, folic acid, 
and ubiquinone. Curcumin is a competitive inhibitor of  
shikimate dehydrogenase[76]. Besides this action, it was 
shown that curcumin administration diminish the expres-
sion of  NF-κB p65 in H. pylori-infected mice. Gastric 
inflammation is associated with increased NF-κB activa-
tion, which appears to be attenuated by curcumin[106]. 
Curcumin also suppresses the expression of, the matrix 
metalloproteinase-3 and -9 inflammatory molecules asso-
ciated to the pathogenesis of  H. pylori infection[76].
Some compounds with a known mechanism of  ac-
tion[107], like propolis (Table 2) are active in vitro but a not 
randomized clinical trial (Table 1) show that propolis was 
not efficient in eradicating H. pylori, which might be related 
to an insufficient dosage[108]. Briefly, caffeic acid phenethyl 
ester, the propolis active compound, is a competitive in-
hibitor of  H. pylori peptide deformylase that catalyzes the 
removal of  formyl group from the N-terminus of  nascent 
polypeptide chains, which is essential for H. pylori sur-
vival[107]. Nevertheless, for the majority of  the compounds 
the active component and the molecular mechanism of  
action (inhibition) against H. pylori remain unknown. 
Limitations and promises
Adverse effects are typically minor than the ones that 
patients taking antibiotics have. The comparative study 
of  Nigella sativa (N. sativa) and triple therapy revealed that 
adverse effects in patients taking N. sativa were minor 
than in patients taking antibiotics[89]. Side effects using 
cinnamon[109] and GutGard[110] were minor as well. Also, 
adverse reactions to flavonoids in humans appear to be 
rare[92].
Even considering that herbs are commonly perceived 
as natural products and thus safe, there is a need to test 
the biological active constituents of  herbs, side effects 
caused by contaminants and drug-herb interactions. The 
safety of  herbs could be obtained by requiring manufac-
turers to register with the FDA (or similar), to proceed 
with mandatory safety tests similar to those required for 
drugs, to require registering all health claims, and to as-
sure that product labels provide an accurate list of  all 
ingredients[61].
CONCLUSION
There is a huge multiplicity of  phytotherapy studies; 
the majority of  them done in vitro by exposing H. pylori 
cultures to the herbs. Some of  these herbs appear very 
promising for fighting H. pylori antibiotic resistant strains. 
However, the mode of  action, the active principle and 
the design of  accurate clinical trials of  promising herbal 
products should be addressed in future studies. Most of  
these phytotherapy approaches uses folk medicine prod-
ucts, especially from Asia (China) and Latin America, 
although other herbs are being tested from countries all 
over the world. For the herbs for which the mechanism 
of  action is known, the anti-H. pylori activity appears to 
include inhibition of  essential bacterial enzymes, while 
the gastroprotective action appears to be related with the 
modulation of  the host immune system and/or attenua-
tion of  inflammation.
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